Paying users zone. Data is hidden behind: .
Get 1-month access to Bristol-Myers Squibb Co. for $17.99, or
get full access to the entire website for at least 3 months from $49.99.
We accept:
This is a one-time payment. There is no automatic renewal.
Bristol-Myers Squibb Co. pages available today for free:
Common Stock Valuation Ratios (Price Multiples)
Valuation ratios measure the quantity of an asset or flaw (e.g., earnings) associated with ownership of a specified claim (e.g., a share of ownership of the enterprise).
Current Valuation Ratios
Bristol-Myers Squibb Co., current price multiples
| Bristol-Myers Squibb Co. | Abbott Laboratories | Becton, Dickinson & Co. | Boston Scientific Corp. | CVS Health Corp. | Danaher Corp. | Edwards Lifesciences Corp. | Intuitive Surgical Inc. | Medtronic PLC | Stryker Corp. | UnitedHealth Group Inc. | Health Care Equipment & Services | Health Care | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||||||||||||
| Current share price (P) | ||||||||||||||||
| No. shares of common stock outstanding | ||||||||||||||||
| Earnings per share (EPS) | ||||||||||||||||
| Operating profit per share | ||||||||||||||||
| Sales per share | ||||||||||||||||
| Book value per share (BVPS) | ||||||||||||||||
| Valuation Ratios (Price Multiples) | ||||||||||||||||
| Price to sales (P/S) | ||||||||||||||||
| Price to book value (P/BV) | ||||||||||||||||
Based on: 10-K (filing date: 2021-02-10).
If the company price multiple is lower then the price multiple of benchmark then company stock is relatively undervalued.
Otherwise, if the company price multiple is higher then the price multiple of benchmark then company stock is relatively overvalued.
Historical Valuation Ratios (Summary)
Bristol-Myers Squibb Co., historical price multiples
| Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | ||
|---|---|---|---|---|---|---|
| Price to earnings (P/E) | ||||||
| Price to operating profit (P/OP) | ||||||
| Price to sales (P/S) | ||||||
| Price to book value (P/BV) |
Based on: 10-K (filing date: 2021-02-10), 10-K (filing date: 2020-02-24), 10-K (filing date: 2019-02-25), 10-K (filing date: 2018-02-13), 10-K (filing date: 2017-02-21).
| Valuation ratio | Description | The company |
|---|---|---|
| P/S ratio | An rationale for the P/S ratio is that sales, as the top line in an income statement, are generally less subject to distortion or manipulation than other fundamentals such as EPS or book value. Sales are also more stable than earnings and never negative. | Bristol-Myers Squibb Co.’s P/S ratio increased from 2018 to 2019 but then decreased significantly from 2019 to 2020. |
| P/BV ratio | The P/BV ratio is interpreted as an indicator of market judgment about the relationship between a company’s required rate of return and its actual rate of return. | Bristol-Myers Squibb Co.’s P/BV ratio decreased from 2018 to 2019 but then slightly increased from 2019 to 2020. |
Price to Earnings (P/E)
Bristol-Myers Squibb Co., historical P/E calculation, comparison to benchmarks
| Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | ||
|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | ||||||
| Selected Financial Data (US$) | ||||||
| Net earnings (loss) attributable to BMS (in millions) | ||||||
| Earnings per share (EPS)2 | ||||||
| Share price1, 3 | ||||||
| Valuation Ratio | ||||||
| P/E ratio4 | ||||||
| Benchmarks | ||||||
| P/E Ratio, Competitors5 | ||||||
| Abbott Laboratories | ||||||
| Becton, Dickinson & Co. | ||||||
| Boston Scientific Corp. | ||||||
| CVS Health Corp. | ||||||
| Danaher Corp. | ||||||
| Edwards Lifesciences Corp. | ||||||
| Intuitive Surgical Inc. | ||||||
| Medtronic PLC | ||||||
| Stryker Corp. | ||||||
| UnitedHealth Group Inc. | ||||||
| P/E Ratio, Sector | ||||||
| Health Care Equipment & Services | ||||||
| P/E Ratio, Industry | ||||||
| Health Care | ||||||
Based on: 10-K (filing date: 2021-02-10), 10-K (filing date: 2020-02-24), 10-K (filing date: 2019-02-25), 10-K (filing date: 2018-02-13), 10-K (filing date: 2017-02-21).
1 Data adjusted for splits and stock dividends.
2 2020 Calculation
EPS = Net earnings (loss) attributable to BMS ÷ No. shares of common stock outstanding
= ÷ =
3 Closing price as at the filing date of Bristol-Myers Squibb Co.’s Annual Report.
4 2020 Calculation
P/E ratio = Share price ÷ EPS
= ÷ =
5 Click competitor name to see calculations.
Price to Operating Profit (P/OP)
Bristol-Myers Squibb Co., historical P/OP calculation, comparison to benchmarks
| Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | ||
|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | ||||||
| Selected Financial Data (US$) | ||||||
| Operating income (loss) (in millions) | ||||||
| Operating profit per share2 | ||||||
| Share price1, 3 | ||||||
| Valuation Ratio | ||||||
| P/OP ratio4 | ||||||
| Benchmarks | ||||||
| P/OP Ratio, Competitors5 | ||||||
| Abbott Laboratories | ||||||
| Becton, Dickinson & Co. | ||||||
| Boston Scientific Corp. | ||||||
| CVS Health Corp. | ||||||
| Danaher Corp. | ||||||
| Edwards Lifesciences Corp. | ||||||
| Intuitive Surgical Inc. | ||||||
| Medtronic PLC | ||||||
| Stryker Corp. | ||||||
| UnitedHealth Group Inc. | ||||||
| P/OP Ratio, Sector | ||||||
| Health Care Equipment & Services | ||||||
| P/OP Ratio, Industry | ||||||
| Health Care | ||||||
Based on: 10-K (filing date: 2021-02-10), 10-K (filing date: 2020-02-24), 10-K (filing date: 2019-02-25), 10-K (filing date: 2018-02-13), 10-K (filing date: 2017-02-21).
1 Data adjusted for splits and stock dividends.
2 2020 Calculation
Operating profit per share = Operating income (loss) ÷ No. shares of common stock outstanding
= ÷ =
3 Closing price as at the filing date of Bristol-Myers Squibb Co.’s Annual Report.
4 2020 Calculation
P/OP ratio = Share price ÷ Operating profit per share
= ÷ =
5 Click competitor name to see calculations.
Price to Sales (P/S)
Bristol-Myers Squibb Co., historical P/S calculation, comparison to benchmarks
| Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | ||
|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | ||||||
| Selected Financial Data (US$) | ||||||
| Revenues (in millions) | ||||||
| Sales per share2 | ||||||
| Share price1, 3 | ||||||
| Valuation Ratio | ||||||
| P/S ratio4 | ||||||
| Benchmarks | ||||||
| P/S Ratio, Competitors5 | ||||||
| Abbott Laboratories | ||||||
| Becton, Dickinson & Co. | ||||||
| Boston Scientific Corp. | ||||||
| CVS Health Corp. | ||||||
| Danaher Corp. | ||||||
| Edwards Lifesciences Corp. | ||||||
| Intuitive Surgical Inc. | ||||||
| Medtronic PLC | ||||||
| Stryker Corp. | ||||||
| UnitedHealth Group Inc. | ||||||
| P/S Ratio, Sector | ||||||
| Health Care Equipment & Services | ||||||
| P/S Ratio, Industry | ||||||
| Health Care | ||||||
Based on: 10-K (filing date: 2021-02-10), 10-K (filing date: 2020-02-24), 10-K (filing date: 2019-02-25), 10-K (filing date: 2018-02-13), 10-K (filing date: 2017-02-21).
1 Data adjusted for splits and stock dividends.
2 2020 Calculation
Sales per share = Revenues ÷ No. shares of common stock outstanding
= ÷ =
3 Closing price as at the filing date of Bristol-Myers Squibb Co.’s Annual Report.
4 2020 Calculation
P/S ratio = Share price ÷ Sales per share
= ÷ =
5 Click competitor name to see calculations.
| Valuation ratio | Description | The company |
|---|---|---|
| P/S ratio | An rationale for the P/S ratio is that sales, as the top line in an income statement, are generally less subject to distortion or manipulation than other fundamentals such as EPS or book value. Sales are also more stable than earnings and never negative. | Bristol-Myers Squibb Co.’s P/S ratio increased from 2018 to 2019 but then decreased significantly from 2019 to 2020. |
Price to Book Value (P/BV)
Bristol-Myers Squibb Co., historical P/BV calculation, comparison to benchmarks
| Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | ||
|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | ||||||
| Selected Financial Data (US$) | ||||||
| Total Bristol-Myers Squibb Company shareholders’ equity (in millions) | ||||||
| Book value per share (BVPS)2 | ||||||
| Share price1, 3 | ||||||
| Valuation Ratio | ||||||
| P/BV ratio4 | ||||||
| Benchmarks | ||||||
| P/BV Ratio, Competitors5 | ||||||
| Abbott Laboratories | ||||||
| Becton, Dickinson & Co. | ||||||
| Boston Scientific Corp. | ||||||
| CVS Health Corp. | ||||||
| Danaher Corp. | ||||||
| Edwards Lifesciences Corp. | ||||||
| Intuitive Surgical Inc. | ||||||
| Medtronic PLC | ||||||
| Stryker Corp. | ||||||
| UnitedHealth Group Inc. | ||||||
| P/BV Ratio, Sector | ||||||
| Health Care Equipment & Services | ||||||
| P/BV Ratio, Industry | ||||||
| Health Care | ||||||
Based on: 10-K (filing date: 2021-02-10), 10-K (filing date: 2020-02-24), 10-K (filing date: 2019-02-25), 10-K (filing date: 2018-02-13), 10-K (filing date: 2017-02-21).
1 Data adjusted for splits and stock dividends.
2 2020 Calculation
BVPS = Total Bristol-Myers Squibb Company shareholders’ equity ÷ No. shares of common stock outstanding
= ÷ =
3 Closing price as at the filing date of Bristol-Myers Squibb Co.’s Annual Report.
4 2020 Calculation
P/BV ratio = Share price ÷ BVPS
= ÷ =
5 Click competitor name to see calculations.
| Valuation ratio | Description | The company |
|---|---|---|
| P/BV ratio | The P/BV ratio is interpreted as an indicator of market judgment about the relationship between a company’s required rate of return and its actual rate of return. | Bristol-Myers Squibb Co.’s P/BV ratio decreased from 2018 to 2019 but then slightly increased from 2019 to 2020. |